Emerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia  

作　　者：Shailendra KAPOOR 

机构地区：[1]2300 East Cary Street Richmond,VA 23223,USA

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2012年第9期761-762,共2页浙江大学学报（英文版）B辑（生物医学与生物技术）

摘　　要：The recent article by Liang et al. （2011）, pub- lished in Journal of Zhejiang University-SCIENCE B （Biomedicine ＆ Biotechnology）, is highly interesting. Interestingly, the past few years have seen the in- creasing application of berbamine as an anti-cancer agent in other systemic malignancies besides chronic myeloid leukemia. For instance, berbamine administration alters the Bcl-2/Bax ratio and mitigates cell migration and thereby augments the anti-proliferative ability of trichostatin A in non-small cell lung cancers （Duan et al., 2010）. Similarly, berbamine inhibits p65 trans- location, up-regulates A20 and increases the activa- tion of the GADD45/c-Jun N-terminal kinase （JNK） pathway, thereby enhancing cellular apoptosis in multiple myelomas （Liang et al., 2009a; 2009b）. Similarly, alteration of the nuclear factor-kappa B （NF-~B） pathway results in enhanced apoptosis in lymphomas （Duet al., 2010）.The recent article by Liang et al. (2011), published in Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), is highly interesting. Interestingly, the past few years have

关 键 词：CLC number  R55 

分 类 号：R733.7[医药卫生—肿瘤]